BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32083303)

  • 21. MUC5AC and MUC5B enhance the characterization of mucinous adenocarcinomas of the lung and predict poor prognosis.
    Kim YK; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Kim MH
    Histopathology; 2015 Oct; 67(4):520-8. PubMed ID: 25786562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas.
    Matsubara D; Yoshimoto T; Soda M; Amano Y; Kihara A; Funaki T; Ito T; Sakuma Y; Shibano T; Endo S; Hagiwara K; Ishikawa S; Fukayama M; Murakami Y; Mano H; Niki T
    Cancer Sci; 2020 Jun; 111(6):2183-2195. PubMed ID: 32237253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
    Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
    J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum.
    Kim DH; Kim JW; Cho JH; Baek SH; Kakar S; Kim GE; Sleisenger MH; Kim YS
    Int J Oncol; 2005 Oct; 27(4):957-64. PubMed ID: 16142311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS).
    Buyuk M; Ozluk Y; Bakkaloglu DV; Ozkan B; Firat P; Yilmazbayhan D
    Turk Patoloji Derg; 2023; 39(1):64-74. PubMed ID: 36367122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MUC5AC, cytokeratin 20 and HER2 expression and K-RAS mutations within mucinogenic growth in congenital pulmonary airway malformations.
    Rossi G; Gasser B; Sartori G; Migaldi M; Costantini M; Mengoli MC; Piccioli S; Cavazza A; Rivasi F
    Histopathology; 2012 Jun; 60(7):1133-43. PubMed ID: 22348416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
    Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
    BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
    Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
    Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
    Ueda D; Ito M; Tsutani Y; Giménez-Capitán A; Román-Lladó R; Pérez-Rosado A; Aguado C; Kushitani K; Miyata Y; Arihiro K; Molina-Vila MA; Rosell R; Takeshima Y; Okada M
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3709-3718. PubMed ID: 33796913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predominant expression of hepatocyte nuclear factor 4α (HNF4α) in thyroid transcription factor-1 (TTF-1)-negative pulmonary adenocarcinoma.
    Kunii R; Jiang S; Hasegawa G; Yamamoto T; Umezu H; Watanabe T; Tsuchida M; Hashimoto T; Hamakubo T; Kodama T; Sasai K; Naito M
    Histopathology; 2011 Feb; 58(3):467-76. PubMed ID: 21348892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK-rearranged adenocarcinoma with extensive mucin production can mimic mucinous adenocarcinoma: clinicopathological analysis and comprehensive histological comparison with KRAS-mutated mucinous adenocarcinoma.
    Cha YJ; Han J; Hwang SH; Lee TB; Kim H; Zo JI
    Pathology; 2016 Jun; 48(4):325-9. PubMed ID: 27114375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor.
    Yonezawa S; Horinouchi M; Osako M; Kubo M; Takao S; Arimura Y; Nagata K; Tanaka S; Sakoda K; Aikou T; Sato E
    Pathol Int; 1999 Jan; 49(1):45-54. PubMed ID: 10227724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung.
    Righi L; Vatrano S; Di Nicolantonio F; Massa F; Rossi G; Cavazza A; Volante M; Votta A; Izzo S; Lo Iacono M; Ardissone F; Di Maio M; Novello S; Scagliotti GV; Papotti M
    J Thorac Oncol; 2016 Apr; 11(4):504-15. PubMed ID: 26774193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol inhibits MUC5AC expression by regulating SPDEF in lung cancer cells.
    Lin YH; Zhu LY; Yang YQ; Zhang ZH; Chen QG; Sun YP; Bi JJ; Luo XM; Ni ZH; Wang XB
    Phytomedicine; 2021 Aug; 89():153601. PubMed ID: 34139546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.